A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive HER2-Negative Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • STATUS
    Recruiting
  • End date
    Jan 22, 2024
  • participants needed
    500
  • sponsor
    Astellas Pharma Global Development, Inc.
Updated on 7 October 2020
Investigator
Medical Affairs Europe
Primary Contact
Site JP81005 (0.0 mi away) Contact
+180 other location

Summary

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS).

This study will also evaluate efficacy, safety and tolerability of zolbetuximab, as well as its effects on quality of life. Pharmacokinetics (PK) of zolbetuximab and the immunogenicity profile of zolbetuximab will be evaluated as well.

Description

The study consists of the following periods: screening; treatment; post-treatment follow up, safety follow up, long term and survival follow-up.

Details
Treatment Capecitabine, Placebo, Oxaliplatin, Zolbetuximab
Clinical Study IdentifierNCT03653507
SponsorAstellas Pharma Global Development, Inc.
Last Modified on7 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Metastatic Gastroesophageal Junction Adenocarcinoma or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Gastric Adenocarcinoma ...?
A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin (hCG) and a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of the following conditions applies
Not a woman of childbearing potential (WOCBP)
WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for 6 months after the final study treatment administration
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study treatment administration
Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study treatment administration
A male subject with female partner(s) of childbearing potential
must agree to use contraception during the treatment period and for 6 months after the final study treatment administration
A male subject must not donate sperm during the treatment period and for 6 months after the final study treatment administration
Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study treatment administration
Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma
Subject has radiologically confirmed locally advanced unresectable or metastatic disease within 28 days prior to randomization
Subject has radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment, 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy
Subject's tumor expresses CLDN18.2 in 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing
Subject has a HER2-negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen
Subject has ECOG performance status 0 or 1
Subject has predicted life expectancy 12 weeks
Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In case of multiple central laboratory data within this period, the most recent data should be used to determine eligibility
Hemoglobin (Hb) 9 g/dl. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb 9 g/dL
Absolute Neutrophil Count (ANC) 1.5x10^9/L
Platelets 100x10^9/L
Albumin 2.5 g/dL
Total Bilirubin 1.5 x upper limit of normal (ULN) without liver metastases (or < 3.0 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 x ULN without liver metastases (or 5 x ULN if liver metastases are present)
Estimated creatinine clearance 30 mL/min
Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) 1.5 x ULN (except for subjects receiving anticoagulation therapy)

Exclusion Criteria

Subject has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo-adjuvant or adjuvant chemotherapy as long as it was completed at least 6 months prior to randomization
Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma 14 days prior to randomization and has not recovered from any related toxicity
Subject has received treatment with herbal medications or other treatments that have known antitumor activity within 28 days prior to randomization
Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed
Subject has received other investigational agents or devices within 28 days prior to randomization
Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies
Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment
Subject has prior severe allergic reaction or intolerance to any component of CAPOX
Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency
Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting
Subject has significant gastric bleeding and/or untreated gastric ulcers that exclude the subject from participation
Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements
For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded
Subjects with positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible
Subjects treated for HCV with undetectable viral load results are eligible
Subject has an active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization
Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization
Subject has significant cardiovascular disease, including any of the following
Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization
History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes
QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female subjects
History or family history of congenital long QT syndrome
Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for > 1 month prior to randomization are eligible)
Subject has a history of central nervous system (CNS) metastases and/or carcinomatous meningitis from gastric/GEJ cancer
Subject has known peripheral sensory neuropathy > grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality
Subject has had a major surgical procedure 28 days prior to randomization
Subject is without complete recovery from a major surgical procedure 14 days prior to randomization
Subject has psychiatric illness or social situations that would preclude study compliance
Subject has another malignancy for which treatment is required
Subject has any concurrent disease, infection, or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet